STERIS

STERIS Plc engages in the provision of healthcare and life science product and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capital equipment. The Applied Sterilization Technologies segment is involved in contract sterilization and testing services for medical device and pharmaceutical manufacturers. The Dental segment provides a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. The company was founded in 1985 and is headquartered in Mentor, OH.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

STERIS plc reports 16% revenue growth and anticipates 7-8% growth in fiscal 2024

STERIS plc's Q4 2023 earnings call highlighted strong revenue growth, successful integration of Cantel Medical, and cost synergies exceeding projections. While challenges exist in the AST segment and concerns were raised about labor costs and free cash flow pressure, the outlook for fiscal 2024 indicates potential opportunities for growth.

STERIS plc reports mixed Q2 performance, optimistic about future opportunities

STERIS plc's Q2 2023 earnings call highlighted mixed performance across segments, with strong growth in Healthcare but challenges in the AST and Dental segments. The company remains optimistic about future opportunities, particularly with the Becton, Dickinson deal and updated financial outlook.

STERIS reports Q3 growth, faces margin pressures and supply challenges

STERIS delivered solid revenue growth despite challenges from divestitures and margin pressures.
The company's strategic acquisitions and focus on direct market access position it for future growth.
While facing some headwinds, STERIS remains confident in its long-term growth prospects.
Investors should monitor how the company navigates supply chain strains and capitalizes on bioprocessing demand.

STERIS reports strong Q4 earnings, eyes growth amid challenges

STERIS delivered robust Q4 2023 results with strong revenue growth and net income.
While facing challenges in certain segments, the company remains optimistic about growth opportunities.
Confidence in compliance with EPA regulations and a positive outlook for fiscal 2024.
Strategic capital allocation decisions and cost synergies driving financial performance.

STERIS reports solid Q1 earnings, eyes growth through acquisitions

STERIS' Q1 2024 performance was solid, driven by revenue growth in the healthcare segment. Challenges were seen in the AST and Dental segments due to inventory destocking. The upcoming acquisition and positive growth expectations in Life Sciences present opportunities for future growth.

STERIS reports strong Q2 performance amidst segment challenges

STERIS showcased robust financial performance in Q2 2024, driven by strong organic revenue growth and solid net income. While facing challenges in certain segments, the company remains optimistic about future growth opportunities and is actively managing its debt and cash flow.

STERIS reports strong Q3 earnings, updates 2024 outlook positively

STERIS showcased solid performance in Q3 2024, driven by strong healthcare and life sciences segments. Challenges in AST and Dental segments were noted, with opportunities seen in updated fiscal 2024 outlook and strategic discussions on margin dynamics and expansion.

STERIS reports 7% revenue growth, anticipates margin improvement ahead

STERIS demonstrated solid revenue growth and maintained free cash flow in line with guidance.
While facing margin challenges in certain segments, the company anticipates improvements ahead.
The outlook for organic revenue growth, adjusted EPS, and free cash flow remains positive for the full year.
Overall, STERIS is strategically positioned to capitalize on growth opportunities and address current challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STERIS Plc engages in the provision of healthcare and life science products and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capital equipment. The Applied Sterilization Technologies segment is involved in contract sterilization and testing services for medical device and pharmaceutical manufacturers. The Dental segment offers a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. The company was founded in 1985 and is headquartered in Dublin, Ireland.

Abbott Labs

Costco

These businesses operate on a large scale but with a narrower focus than Amazon.

3 Stalwart Stocks That Could Be Safer Than Amazon

Steris (STE) reported earnings 30 days ago. What's next for the stock?

Steris (STE) Up 1.5% Since Last Earnings Report: Can It Continue?

AstraZeneca

Sanofi

Market downturns don't affect stocks equally.

3 Unstoppable Stocks That Are Higher Than Before the Market Correction

Investors are optimistic about STERIS (STE) due to its strong fiscal fourth-quarter results.

Here's Why You Should Hold STERIS (STE) Stock in Your Portfolio

STERIS plc. (NYSE:STE ) Q4 2022 Earnings Conference Call May 12, 2022 10:00 AM ET Company Participants Daniel Carestio – President and Chief Executive Officer Michael Tokich – Senior Vice President and Chief Operating Officer Julie Winter – Investor Relations Conference Call Participants Chris Cooley – Stephens Inc Mike Matson – Needham Matthew Mishan – KeyBank David Turkaly – JMP Securities Operator Good day and welcome to the Steris PLC Fourth Quarter 2022 Results Conference Call.

STERIS plc. (STE) CEO Daniel Carestio on Q4 2022 Results - Earnings Call Transcript

Robust performances across all four reporting segments drive STERIS' (STE) fiscal fourth-quarter revenues.

STERIS (STE) Q4 Earnings Surpass Estimates, Gross Margin Rises

DUBLIN, IRELAND, May 11, 2022 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2022 fourth quarter ended March 31, 2022. Revenue as reported for the quarter increased 39% to $1.2 billion compared with $873.5 million in the fourth quarter of fiscal 2021. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 11% for the fourth quarter of fiscal 2022 as compared to the fourth quarter of fiscal 2021.

STERIS Announces Financial Results for Fiscal 2022 Fourth Quarter and Full Year

DUBLIN, IRELAND , May 04, 2022 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.43 per share. The dividend is payable June 28, 2022 to shareholders of record at the close of business on June 14, 2022.

STERIS Declares $0.43 per share Dividend

DUBLIN, IRELAND, April 25, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2022 fourth quarter and full year financial results at 10:00 a.m. ET on May 12, 2022. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.

STERIS to Host a Conference Call for Fiscal 2022 Fourth Quarter and Full Year Financial Results on May 12, 2022

It isn't going to be facing disruption anytime soon.

This Is the Perfect Healthcare Stock to Buy and Hold for Decades

Investors are optimistic about STERIS' (STE) robust segmental growth and noteworthy acquisitions in the healthcare and pharmaceutical spaces.

STERIS (STE) Up 8% Since Q3 Earnings: What's Driving It?

Investors are optimistic about STERIS (STE) on impressive growth across its operating segments.

STERIS (STE) Hits a New 52-Week High: What's Driving It?

Investors are optimistic about STERIS' (STE) robust segmental performance and upbeat 2022 guidance.

Here's Why You Should Retain STERIS (STE) Stock For Now

Why Is Steris (STE) Down 3.7% Since Last Earnings Report?

STERIS' (STE) significant revenues from acquisitions of Key Surgical and Cantel Medical appear promising.

STERIS (STE) Strategic Buyouts Aid Growth, Margin Woe Stays

Investors are optimistic about STERIS (STE) on its better-than-expected earnings in the fiscal third quarter and the ongoing integration of the Cantel Medical business.

Here's Why You Should Hold on to STERIS (STE) Stock for Now

Is Steris a Warren Buffett Stock?

STERIS (STE) reports better-than-expected earnings for the third quarter of fiscal 2022 and robust segmental growth driving the top line.

STERIS (STE) Q3 Earnings Surpass Estimates, Revenues Miss

STERIS plc. (STE) CEO Dan Carestio on Q3 2022 Results - Earnings Call Transcript

Steris (STE) delivered earnings and revenue surprises of 8.72% and 0.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Steris (STE) Surpasses Q3 Earnings Estimates

DUBLIN, IRELAND, Feb. 08, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2022 third quarter ended December 31, 2021. Revenue as reported for the quarter increased 49% to $1.2 billion compared with $808.9 million in the third quarter of fiscal 2021. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 9% for the third quarter of fiscal 2022 as compared to the third quarter of fiscal 2021.

STERIS Announces Financial Results for Fiscal 2022 Third Quarter

There are medical emergency times when both a National Emergency and a Personal Emergency must have attention. People skills, facilities, time will be shared to preserve life. Easiest to picture is a failed heart valve replacement. Do or die. Now.

Steris: Another Essential Healthcare Supply Resource

DUBLIN, IRELAND, Jan. 25, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2022 third quarter financial results at 10:00 a.m. ET on February 9, 2022. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.

STERIS to Host a Conference Call for Fiscal 2022 Third Quarter Financial Results on February 9, 2022

Evoqua Water Technologies

PITTSBURGH--(BUSINESS WIRE)--Evoqua Water Technologies Closes Acquisition of Renal Business from STERIS

Evoqua Water Technologies Closes Acquisition of Renal Business from STERIS

Steris (STE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

News for STERIS Stock (STE)